BACKGROUND: The radiosurgical treatment of vestibular schwannomas in patients with neurofibromatosis type 2 (NF2) is controversial. The authors investigated the radiologically proven tumor control rate after gamma knife radiosurgery. The factors that affect tumor control and serviceable hearing preservation were analyzed. METHODS: Thirty-six lesions in 30 patients were included. The median lengths of the clinical and radiologic follow-ups were 48.5 months and 36.5 months, respectively. The median tumor volume was 3.2 cm3. The mean marginal dose was 12.1 grays (Gy) (range, 8-14 Gy) at an isodose line of 50%+/-0.6%. The Kaplan-Meier method and Cox proportional hazards model were used for the statistical analyses. RESULTS: The actuarial tumor control rate was 81%, 74%, and 66%, respectively, in the first, second, and fifth years. Five tumors required a salvage surgery because of tumor control failure. A low marginal dose and a young age at radiosurgery were associated with poor tumor control. Of the 16 tumors with which ipsilateral hearing was serviceable, the actuarial serviceable hearing preservation rates were 50%, 45%, and 33%, respectively, in the first, second, and fifth years. Better ipsilateral hearing (Gardner-Robertson grade 1, compared with grade 2) at the time of radiosurgery was associated with significantly greater serviceable hearing preservation. CONCLUSIONS: Gamma knife radiosurgery for vestibular schwannomas in NF2 patients provided 5-year tumor control in approximately two-thirds of patients and preserved serviceable hearing in approximately one-third. The rates of other cranial nerve deficits were low, and no secondary malignancy was observed. Radiosurgery should be included in treatment options for NF2 patients. Copyright (c) 2009 American Cancer Society.
BACKGROUND: The radiosurgical treatment of vestibular schwannomas in patients with neurofibromatosis type 2 (NF2) is controversial. The authors investigated the radiologically proven tumor control rate after gamma knife radiosurgery. The factors that affect tumor control and serviceable hearing preservation were analyzed. METHODS: Thirty-six lesions in 30 patients were included. The median lengths of the clinical and radiologic follow-ups were 48.5 months and 36.5 months, respectively. The median tumor volume was 3.2 cm3. The mean marginal dose was 12.1 grays (Gy) (range, 8-14 Gy) at an isodose line of 50%+/-0.6%. The Kaplan-Meier method and Cox proportional hazards model were used for the statistical analyses. RESULTS: The actuarial tumor control rate was 81%, 74%, and 66%, respectively, in the first, second, and fifth years. Five tumors required a salvage surgery because of tumor control failure. A low marginal dose and a young age at radiosurgery were associated with poor tumor control. Of the 16 tumors with which ipsilateral hearing was serviceable, the actuarial serviceable hearing preservation rates were 50%, 45%, and 33%, respectively, in the first, second, and fifth years. Better ipsilateral hearing (Gardner-Robertson grade 1, compared with grade 2) at the time of radiosurgery was associated with significantly greater serviceable hearing preservation. CONCLUSIONS: Gamma knife radiosurgery for vestibular schwannomas in NF2patients provided 5-year tumor control in approximately two-thirds of patients and preserved serviceable hearing in approximately one-third. The rates of other cranial nerve deficits were low, and no secondary malignancy was observed. Radiosurgery should be included in treatment options for NF2patients. Copyright (c) 2009 American Cancer Society.
Authors: Siegal Sadetzki; Revital Bruchim; Bernice Oberman; Georgina N Armstrong; Ching C Lau; Elizabeth B Claus; Jill S Barnholtz-Sloan; Dora Il'yasova; Joellen Schildkraut; Christoffer Johansen; Richard S Houlston; Sanjay Shete; Christopher I Amos; Jonine L Bernstein; Sara H Olson; Robert B Jenkins; Daniel Lachance; Nicholas A Vick; Ryan Merrell; Margaret Wrensch; Faith G Davis; Bridget J McCarthy; Rose Lai; Beatrice S Melin; Melissa L Bondy Journal: Eur J Cancer Date: 2013-01-04 Impact factor: 9.162
Authors: Ramita Dewan; Alex Pemov; H Jeffrey Kim; Keaton L Morgan; Raul A Vasquez; Prashant Chittiboina; Xiang Wang; Settara C Chandrasekharappa; Abhik Ray-Chaudhury; John A Butman; Douglas R Stewart; Ashok R Asthagiri Journal: Neuro Oncol Date: 2014-12-01 Impact factor: 12.300
Authors: Georgios Kontorinis; Jaya Nichani; Simon R Freeman; Scott A Rutherford; Samantha Mills; Andrew T King; Deborah Mawman; Sue Huson; Martin O'Driscoll; D Gareth Evans; Simon K W Lloyd Journal: Eur Arch Otorhinolaryngol Date: 2014-10-08 Impact factor: 2.503
Authors: Iddo Paldor; Sara Abbadi; Nicolas Bonne; Xiaobu Ye; Fausto J Rodriguez; David Rowshanshad; MariaLisa Itzoe; Veronica Vigilar; Marco Giovannini; Henry Brem; Jaishri O Blakeley; Betty M Tyler Journal: J Neurooncol Date: 2017-07-22 Impact factor: 4.130
Authors: Scott R Plotkin; Chris Halpin; Jaishri O Blakeley; William H Slattery; D Bradley Welling; Susan M Chang; Jay S Loeffler; Gordon J Harris; A Gregory Sorensen; Michael J McKenna; Fred G Barker Journal: J Neurooncol Date: 2009-05-09 Impact factor: 4.130
Authors: Umberto Tosi; Omri Maayan; Anjile An; Miguel E Tusa Lavieri; Sergio W Guadix; Antonio P DeRosa; Paul J Christos; Susan Pannullo; Philip E Stieg; Andrew Brandmaier; Jonathan P S Knisely; Rohan Ramakrishna Journal: J Neurooncol Date: 2022-01-18 Impact factor: 4.130
Authors: Said Farschtschi; Victor-Felix Mautner; Anna Cecilia Lawson McLean; Alexander Schulz; Reinhard E Friedrich; Steffen K Rosahl Journal: Dtsch Arztebl Int Date: 2020-05-15 Impact factor: 5.594